Abstract: A compound of formula IV: as well as drug-linkers and conjugates comprising this compound, and the use of the conjugates in treating cancer.

Abstract: A compound which is either A: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.

Abstract: There is described a multi-unit dose dry powder medicament delivery device (1) comprising: a first element (2) comprising a single use nozzle (3) located in a body (4) which is at least partially lined with an inner member, an inner sleeve (6) comprising an airway (5) and a cartridge seat (11); and a second element (20) adapted to be releasably attached to the first element (2), said second element (20) comprising an actuator provided with an air source (23) and a valve (22); wherein the medicament cartridge comprises a replaceable cartridge, e.g. a replaceable pre-dosed cartridge.

Abstract: A method, including: receiving observation data from one or more data-capturing devices, the observation data representing a presence of an individual; processing the observation data to generate identity data representing the identity of the individual, and to detect at least one physiological characteristic or behavioural characteristic of the individual; retrieving behavioural profile data of the individual based on the identity data; and comparing the detected characteristic to at least one expected characteristic represented by the behavioural profile data of the individual to identify an abnormality of the individual.

Abstract: An analyte sensor is disclosed. The analyte sensor includes an implantable sensor configured to measure a signal indicative of an analyte concentration in a user and at least one membrane layer. The membrane layer is disposed over at least a portion of the sensor. The membrane includes a membrane polymer matrix including an ethylene vinyl acetate copolymer and a therapeutic agent dispersed within the membrane polymer matrix. The membrane layer is permeable to an analyte. Devices and methods for monitoring analytes are also disclosed.

Abstract: There is described a multi-unit dose dry powder medicament delivery device comprising: a first element comprising a single use nozzle located in a body which is at least partially lined with an inner member, said inner sleeve comprising an airway and a cartridge seat; and a second element adapted to be releasably attached to the first element, said second element comprising an actuator provided with an air source and a valve.

Abstract: A compound which is either A: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.

Abstract: Conjugates of an antibody that binds to CD25 with PBD dimers.

Abstract: Conjugates of an antibody that binds to CD19 with PBD dimers.

Abstract: Embodiments herein describe using visual passwords to control access to secure information. When a user attempts to access the secure information, she can provide her username to an authentication agent which identifies the visual password corresponding to the received username and selects a first set of images that contains the visual password and a second set of images that does not. The first and second sets of images are then transmitted to a user device. The user device can display the first and second sets of images to the user who selects which images have the visual password. An indication of which images the user selected is then transmitted to the authentication engine which determines whether the user selected all the images in the first set and none of the images in the second set. If so, the user is granted access to the secure information.

Abstract: A compound which is either A: or B: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.

Abstract: Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.

Abstract: The disclosure provides conjugates of an isolated humanized anti-CD22 antibody and PBD dimers.

Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.

Abstract: A conjugate of formula (I) wherein Ab is a modified antibody having at least one free conjugation site on each heavy chain.

Abstract: A conjugate of formula I: L-(DL)p??(I) wherein L is a Ligand unit, DL is a Drug Linker unit of formula II: wherein either: (a) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (b) R11 is OH, and R10 is: p is an integer of from 1 to 20.

Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.

Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): where Y is H or F, with a single overall linker moiety connecting two topoisomerase inhibitor derivatives to a Ligand Unit, wherein the topoisomerase inhibitor derivatives are cleavable from the Ligand Unit. Also provided is A* with the linking unit attached, and intermediates for their synthesis.

Abstract: A compound with the formula I: (I) and salts and solvates thereof, wherein: R? is a group of formula II: (II) where each of n and m are independently selected from 1, 2 and 3.

Abstract: A conjugate of formula I: L-(DL)P??(1) wherein L is a Ligand unit, DL is a Drug Linker unit of formula II: wherein either: (a) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (b) R11 is OH, and R10 is: p is an integer of from 1 to 20.